Savara Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
SVRA Nasdaq 2834 www.savarapharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Savara Inc.

Savara Announces New Employment Inducement Grant - Aug 20th, 2026 2:05 pm
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update - Aug 11th, 2026 2:05 pm
What Insmed Stock's Premium Is Actually Buying - Aug 7th, 2026 9:39 am
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041 - Jul 30th, 2026 6:05 am
Here's Why You Should Add Savara Stock to Your Portfolio Now - Jul 22nd, 2026 7:21 am
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline - Jun 27th, 2026 9:34 am
Savara Announces Chief Financial and Administrative Officer Transition - Jun 8th, 2026 2:05 pm
Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns - Jun 8th, 2026 11:13 am
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally - May 23rd, 2026 4:33 pm
Savara Inc. (SVRA) Reports Q1 Financial Results - May 22nd, 2026 12:43 pm
US High Growth Tech Stocks To Watch - Apr 27th, 2026 11:38 am
Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim - Apr 26th, 2026 11:03 am